Progress in the diagnosis and treatment of extensive-stage small cell lung cancer

• 机 构: Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science an
• 出 处: 肿瘤学与转化医学（英文）
• 发表日期: 2019年1期
• 关键词: small cell lung cancer (SCLC) extensive-stage targeted therapy immunotherapy

Lung cancer, being the most common cancer type, accounts for 13% of all newly diagnosed malignant tumors globally each year. Small cell lung cancer (SCLC) accounts for approximately 15% of newly diagnosed lung cancers each year, but its annual death toll accounts for 25% of that of lung cancer. We summarized relevant clinical studies to elaborate the epidemiology, pathological and clinical characteristics and the treatment status of small cell lung cancer. This paper first described the epidemiology and the pathological and clinical characteristics of SCLC and the systematic treatment of extensive-stage SCLC and then introduced the current targeted therapy and immunotherapy for SCLC to provide clinicians and patients with a more systematic, comprehensive, and beneficial treatment regimen. We expect that these studies can provide clinicians with a clear direction in molecularly targeted therapy or immunotherapy, so that a treatment approach with better antitumor effects and longer-lasting clinical benefits can be provided to the patients.